Geron Corporation (GERN) News
Filter GERN News Items
GERN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GERN News Highlights
- GERN's 30 day story count now stands at 6.
- Over the past 15 days, the trend for GERN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about GERN are ASH, FRO and KOD.
Latest GERN News From Around the Web
Below are the latest news stories about GERON CORP that investors may wish to consider to help them evaluate GERN as an investment opportunity.
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)FOSTER CITY, Calif., December 21, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 417,490 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. |
Geron (GERN) Upgraded to Buy: Here's WhyGeron (GERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue?Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDSFOSTER CITY, Calif., December 11, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced presentations of data from its IMerge Phase 3 clinical trial evaluating first-in-class investigational telomerase inhibitor imetelstat in patients with lower risk myelodysplastic syndromes (MDS), as well as population analysis of claims data in lower risk MDS. The data were presented at the American Society of Hematology (ASH) Annual Meeting, taking place fro |
Recent uptick might appease Geron Corporation (NASDAQ:GERN) institutional owners after losing 13% over the past yearKey Insights Significantly high institutional ownership implies Geron's stock price is sensitive to their trading... |
Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory MyelofibrosisFOSTER CITY, Calif., December 06, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the Phase 3 IMpactMF clinical trial investigating the Company’s first-in-class telomerase inhibitor, imetelstat, versus best available therapy (BAT) in patients with relapsed/refractory myelofibrosis (MF). |
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDSFOSTER CITY, Calif., December 04, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced publication in The Lancet of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in patients with lower risk myelodysplastic syndromes (MDS) relapsed/refractory or ineligible for erythropoiesis stimulating agents (ESAs). The publication is available online and will be available in print at a later date. |
Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of DirectorsFOSTER CITY, Calif., November 28, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company’s Board of Directors. Dr. Aggarwal has been a prominent investor in the life sciences sector for more than two decades and has a history of expertise in financial and corporate strategy, as well as business development, in companies with which he has been affiliated at both an operational and board leve |
Geron to Participate at Upcoming Investor Conferences in NovemberFOSTER CITY, Calif., November 07, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences: |
7 Stocks to Buy if You Anticipate a Hot NovemberWhile enough evidence exists that justify a pessimistic view of the market – in particular, high inflation and high borrowing costs – it’s also possible that a hot November could rejuvenate previously embattled stocks to buy. |